hVIVO - hMPV Challenge Model Update

hVIVO plc announces that it has successfully completed a pilot characterisation study for its human metapneumovirus (hMPV) strain A2 challenge agent, demonstrating proof-of-concept for a future hVIVO hMPV challenge model to test new vaccines and antivirals.

Dr. Andrew Catchpole
Chief Scientific Officer, hVIVO

Company Events - HVIVO PLC